Talking the Cure by Hogan Lovells Cadwalader https://talkingthecure.podbean.com Hogan Lovells Calwalader is always thinking about how to conquer and foresee the most significant industry issues facing our clients. Hear first-hand from our lawyers around the world on significant developments in the Life Sciences & Health Care sector and why they are so passionate about the industry. We unpack new and exciting industry trends and bring you more outside perspectives to keep you ahead of the curve.

]]> Mon, 20 Oct 2025 19:21:56 +0200 https://podbean.com/?v=5.5 en-us Copyright 2026. All rights reserved. Business 1440 episodic Hogan Lovells is always thinking about how to conquer and foresee the most significant industry issues facing our clients. If you’ve been following us for the past two years, you’ve heard first-hand from our lawyers around the world on significant developments in the Life Sciences & Health Care sector and why they are so passionate about the industry. In season 3, we’ll unpack new and exciting industry trends and bring you more outside perspectives to keep you ahead of the curve. Hogan Lovells Cadwalader Hogan Lovells Cadwalader No false https://feed.podbean.com/talkingthecure/feed.xml https://pbcdn1.podbean.com/imglogo/image-logo/9831299/Talking_the_Cure_Podcast_old_brand.jpg Talking the Cure by Hogan Lovells Cadwalader https://talkingthecure.podbean.com 144 144 It’s a Brave New World: Pharma ad/promo enforcement is changing in the U.S. and Europe, and companies should, too It’s a Brave New World: Pharma ad/promo enforcement is changing in the U.S. and Europe, and companies should, too https://talkingthecure.podbean.com/e/it-s-a-brave-new-world-pharma-adpromo-enforcement-is-changing-in-the-us-and-europe-and-companies-should-too/ https://talkingthecure.podbean.com/e/it-s-a-brave-new-world-pharma-adpromo-enforcement-is-changing-in-the-us-and-europe-and-companies-should-too/#comments Mon, 20 Oct 2025 19:21:56 +0200 talkingthecurebyhoganlovells.podbean.com/1c07ebec-b853-370b-9c16-97780161bb9e FDA’s recent splash of 100+ enforcement letters objecting to drug advertising looks like a trend, not a blip.  And although the UK and EU prohibit DTC ads for Rx drugs, there are new efforts creating risk for pharma companies, even if they’re not the main focus.  In this episode of Talking the Cure, host Phil Katz is joined by Heidi Gertner, Sally Gu, and Bonella Ramsay to unpack what’s happening and what it means pharma companies should be thinking about, and steps they should be taking now to mitigate current – and future – risks. 

]]> FDA’s recent splash of 100+ enforcement letters objecting to drug advertising looks like a trend, not a blip.  And although the UK and EU prohibit DTC ads for Rx drugs, there are new efforts creating risk for pharma companies, even if they’re not the main focus.  In this episode of Talking the Cure, host Phil Katz is joined by Heidi Gertner, Sally Gu, and Bonella Ramsay to unpack what’s happening and what it means pharma companies should be thinking about, and steps they should be taking now to mitigate current – and future – risks. 

]]> Hogan Lovells false No 1581 27 full The future of drug pricing: IRA, MFN, and tariff pressures explained The future of drug pricing: IRA, MFN, and tariff pressures explained https://talkingthecure.podbean.com/e/the-future-of-drug-pricing-ira-mfn-and-tariff-pressures-explained/ https://talkingthecure.podbean.com/e/the-future-of-drug-pricing-ira-mfn-and-tariff-pressures-explained/#comments Mon, 22 Sep 2025 19:48:45 +0200 talkingthecurebyhoganlovells.podbean.com/ec41c652-4f29-3194-befc-f4e4ef9055e2 In this episode of Talking the Cure, Hogan Lovells partners Phil Katz, Alice Valder Curren, and Jane Summerfield discuss the evolving landscape of pharmaceutical pricing, particularly legislative and administrative changes in the United States and their implications in Europe. The discussion includes the Inflation Reduction Act (IRA) in the U.S., Most Favored Nations (MFN) pricing policies, and the impact of tariffs on drug prices and supply chains.

]]> In this episode of Talking the Cure, Hogan Lovells partners Phil Katz, Alice Valder Curren, and Jane Summerfield discuss the evolving landscape of pharmaceutical pricing, particularly legislative and administrative changes in the United States and their implications in Europe. The discussion includes the Inflation Reduction Act (IRA) in the U.S., Most Favored Nations (MFN) pricing policies, and the impact of tariffs on drug prices and supply chains.

]]> Hogan Lovells false No 1278 26 full AI at the crossroads: Global developments shaping life sciences AI at the crossroads: Global developments shaping life sciences https://talkingthecure.podbean.com/e/ai-at-the-crossroads-global-developments-shaping-life-sciences/ https://talkingthecure.podbean.com/e/ai-at-the-crossroads-global-developments-shaping-life-sciences/#comments Tue, 29 Jul 2025 17:28:39 +0200 talkingthecurebyhoganlovells.podbean.com/747df714-1f7d-394e-8d32-d5eb6ba9cf5d In this episode of Talking the Cure, Hogan Lovells partners Phil Katz, Melissa Bianchi, and Jodi Scott explore how artificial intelligence is transforming the pharmaceutical, biotech, and medical device industries. From AI-driven clinical trials and diagnostic tools to regulatory challenges and global compliance complexities, the discussion dives deep into both the promise and the pitfalls of integrating AI in health care. Tune in to hear how industry leaders are navigating this fast-evolving space – and what companies need to know to stay ahead.

]]> In this episode of Talking the Cure, Hogan Lovells partners Phil Katz, Melissa Bianchi, and Jodi Scott explore how artificial intelligence is transforming the pharmaceutical, biotech, and medical device industries. From AI-driven clinical trials and diagnostic tools to regulatory challenges and global compliance complexities, the discussion dives deep into both the promise and the pitfalls of integrating AI in health care. Tune in to hear how industry leaders are navigating this fast-evolving space – and what companies need to know to stay ahead.

]]> Hogan Lovells false No 1644 25 full Planning the Pivot: Onshoring Pharma/Biotech Manufacturing in a Brave New World Planning the Pivot: Onshoring Pharma/Biotech Manufacturing in a Brave New World https://talkingthecure.podbean.com/e/planning-the-pivot-onshoring-pharmabiotech-manufacturing-in-a-brave-new-world/ https://talkingthecure.podbean.com/e/planning-the-pivot-onshoring-pharmabiotech-manufacturing-in-a-brave-new-world/#comments Mon, 09 Jun 2025 10:33:28 +0200 talkingthecurebyhoganlovells.podbean.com/458ab001-9a65-324e-92fd-37acc1220aa6 Starting with tariffs and Executive Orders, there are myriad incentives – some would say imperatives – for pharma and biotech companies to increase and expand manufacturing in the US.  But this is a classic “easier said than done” situation, for a number of reasons.  Sally Gu and Chris Middendorf, drug manufacturing and quality experts and leading members of the Hogan Lovells Pharma/Biotech Regulatory Compliance and Enforcement Practice, join Phil Katz to dive into one particular set of issues – those related to the technical, logistical and other practical considerations of manufacturing these products.  Drawing on their years of experience advising and advocating for product sponsors, manufacturers, and others on how to efficiently and compliantly manufacture or source drug and biotechnology products, Sally and Chris tackle the challenges in adding or changing manufacturing sites.  They bring an integrated and strategic approach, and discuss how companies can (and should) do the same.

]]> Starting with tariffs and Executive Orders, there are myriad incentives – some would say imperatives – for pharma and biotech companies to increase and expand manufacturing in the US.  But this is a classic “easier said than done” situation, for a number of reasons.  Sally Gu and Chris Middendorf, drug manufacturing and quality experts and leading members of the Hogan Lovells Pharma/Biotech Regulatory Compliance and Enforcement Practice, join Phil Katz to dive into one particular set of issues – those related to the technical, logistical and other practical considerations of manufacturing these products.  Drawing on their years of experience advising and advocating for product sponsors, manufacturers, and others on how to efficiently and compliantly manufacture or source drug and biotechnology products, Sally and Chris tackle the challenges in adding or changing manufacturing sites.  They bring an integrated and strategic approach, and discuss how companies can (and should) do the same.

]]> Hogan Lovells false No 1749 24 full A cure worse than the disease?  Using tariffs to bolster U.S. pharma manufacturing A cure worse than the disease?  Using tariffs to bolster U.S. pharma manufacturing https://talkingthecure.podbean.com/e/a-cure-worse-than-the-disease%c2%a0-using-tariffs-to-bolster-us-pharma-manufacturing/ https://talkingthecure.podbean.com/e/a-cure-worse-than-the-disease%c2%a0-using-tariffs-to-bolster-us-pharma-manufacturing/#comments Fri, 09 May 2025 18:35:34 +0200 talkingthecurebyhoganlovells.podbean.com/ce712764-6b87-32b5-83d6-0a2a9f626370 In this episode of Talking the Cure, Phil Katz talks with Cybil Roehrenbeck, Josh Gelula, and Kelly Zhang about the announced and seemingly ever-changing plans for tariffs on imported goods – and pharmaceutical products in particular – may effect the industry, as well as the availability and cost of drugs.  The discussion unpacks the law, the politics, and policy to offer suggestions on steps businesses can be taking to deal with the impacts.

]]> In this episode of Talking the Cure, Phil Katz talks with Cybil Roehrenbeck, Josh Gelula, and Kelly Zhang about the announced and seemingly ever-changing plans for tariffs on imported goods – and pharmaceutical products in particular – may effect the industry, as well as the availability and cost of drugs.  The discussion unpacks the law, the politics, and policy to offer suggestions on steps businesses can be taking to deal with the impacts.

]]> Hogan Lovells false No 1674 23 full Pharma – The Last Word – Breaking Barriers: The FDA’s Evolving Approach to Biosimilars and Interchangeability Pharma – The Last Word – Breaking Barriers: The FDA’s Evolving Approach to Biosimilars and Interchangeability https://talkingthecure.podbean.com/e/pharma-the-last-word-breaking-barriers-the-fda-s-evolving-approach-to-biosimilars-and-interchangeability/ https://talkingthecure.podbean.com/e/pharma-the-last-word-breaking-barriers-the-fda-s-evolving-approach-to-biosimilars-and-interchangeability/#comments Wed, 25 Sep 2024 07:41:53 +0200 talkingthecurebyhoganlovells.podbean.com/4773c391-b375-37f7-9a13-2d5c544345e5 In this episode, host Phil Katz sits down with Deborah Cho, to discuss the evolving landscape of biosimilarity and interchangeability. They dive into the FDA's changing approach, highlighting the shift towards treating biosimilars and interchangeable biosimilars as a single category. Deborah explains how advancements in technology and experience have reduced the need for additional studies, and why the FDA is pushing for a statutory change to streamline approvals. 

The future episodes will focus on specific areas of the law, such as drug development, clinical trials, FDA compliance, and more, providing listeners with a detailed look at the complexities of pharmaceutical regulations and practical strategies for navigating them.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> In this episode, host Phil Katz sits down with Deborah Cho, to discuss the evolving landscape of biosimilarity and interchangeability. They dive into the FDA's changing approach, highlighting the shift towards treating biosimilars and interchangeable biosimilars as a single category. Deborah explains how advancements in technology and experience have reduced the need for additional studies, and why the FDA is pushing for a statutory change to streamline approvals. 

The future episodes will focus on specific areas of the law, such as drug development, clinical trials, FDA compliance, and more, providing listeners with a detailed look at the complexities of pharmaceutical regulations and practical strategies for navigating them.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> In this episode, host Phil Katz sits down with Deborah Cho, a legal expert in biologics and biosimilars, to discuss the evolving landscape of biosimilarity and interchangeability. They dive into the FDA’s changing approach, highlighting the shift towards treating biosimilars and interchangeable biosimilars as a single category. Deborah explains how advancements in technology and experience have reduced the need for additional studies, and why the FDA is pushing for a statutory change to streamline approvals. Hogan Lovells false No 1348 22 full Drafting the Future: Unpacking the FDA's Clinical Trial Diversity Action Plan Drafting the Future: Unpacking the FDA's Clinical Trial Diversity Action Plan https://talkingthecure.podbean.com/e/drafting-the-future-unpacking-the-fdas-clinical-trial-diversity-action-plan/ https://talkingthecure.podbean.com/e/drafting-the-future-unpacking-the-fdas-clinical-trial-diversity-action-plan/#comments Fri, 12 Jul 2024 06:00:00 +0200 talkingthecurebyhoganlovells.podbean.com/3b837246-80c4-33ed-9591-01ffa726f77e In the third part of our clinical trial diversity series, Deborah Cho, Stephanie Agu, and Ashley Grey dissect FDA's new draft guidance on Diversity Action Plans for clinical trials, released on June 28, 2024. Discover what this pivotal document means for clinical trial design and conduct, and its implications for drug and biologic sponsors. Tune in for an insightful discussion on the future of clinical trials and FDA recommendations to ensure diverse participant inclusion.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> In the third part of our clinical trial diversity series, Deborah Cho, Stephanie Agu, and Ashley Grey dissect FDA's new draft guidance on Diversity Action Plans for clinical trials, released on June 28, 2024. Discover what this pivotal document means for clinical trial design and conduct, and its implications for drug and biologic sponsors. Tune in for an insightful discussion on the future of clinical trials and FDA recommendations to ensure diverse participant inclusion.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> In this episode of the third part of the clinical trial diversity series, Ashley Gray, Deborah Chow and Stephanie Agu dissect the FDA’s new draft guidance on the Clinical Trial Diversity Action Plan, released on June 28, 2024. Discover how this pivotal document influences clinical trial design and conduct, thoroughly exploring its implications for drug and biologic sponsors. Tune in for an insightful discussion on the future of clinical trials and the strategies to ensure diverse and effective participant inclusion. Hogan Lovells false No 843 4 6 full Pharma – The Last Word – Early Access Unlocked, navigating EU programs for pre-approval drug access Pharma – The Last Word – Early Access Unlocked, navigating EU programs for pre-approval drug access https://talkingthecure.podbean.com/e/pharma-the-last-word-early-access-unlocked-navigating-eu-programs-for-pre-approval-drug-access/ https://talkingthecure.podbean.com/e/pharma-the-last-word-early-access-unlocked-navigating-eu-programs-for-pre-approval-drug-access/#comments Fri, 28 Jun 2024 11:29:12 +0200 talkingthecurebyhoganlovells.podbean.com/0fc6484b-d0f6-37a7-8b08-1c47694e0d30 In this episode Phil Katz and Hein van den Bos discuss early access programs in the EU, exploring the various types of programs, their practical implications, and the regulatory challenges. They delve into compassionate use programs, named patient supply, and the nuances of implementing these programs across different EU countries. The conversation also touches on the benefits and risks of early access, including potential ethical and reputational concerns.

The future episodes will focus on specific areas of the law, such as drug development, clinical trials, FDA compliance, and more, providing listeners with a detailed look at the complexities of pharmaceutical regulations and practical strategies for navigating them.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> In this episode Phil Katz and Hein van den Bos discuss early access programs in the EU, exploring the various types of programs, their practical implications, and the regulatory challenges. They delve into compassionate use programs, named patient supply, and the nuances of implementing these programs across different EU countries. The conversation also touches on the benefits and risks of early access, including potential ethical and reputational concerns.

The future episodes will focus on specific areas of the law, such as drug development, clinical trials, FDA compliance, and more, providing listeners with a detailed look at the complexities of pharmaceutical regulations and practical strategies for navigating them.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> Hogan Lovells false No 1060 21 full Pharma – The Last Word – Regulatory and legal trends in the pharma and biotech industries Pharma – The Last Word – Regulatory and legal trends in the pharma and biotech industries https://talkingthecure.podbean.com/e/pharma-the-last-word-the-inaugural-episode-1717150210/ https://talkingthecure.podbean.com/e/pharma-the-last-word-the-inaugural-episode-1717150210/#comments Fri, 31 May 2024 12:10:10 +0200 talkingthecurebyhoganlovells.podbean.com/87a5535c-43d8-35da-9304-91b34c169650 In this episode host Phil Katz, discusses regulatory and legal trends in the pharma and biotech industries with Komal Karnik Nigam. They delve into the FDA's evolving approach to data packages required for drug approval, highlighting the increased flexibility in accepting alternative forms of evidence. Komal explains how FDA's guidance has shifted from demanding large, multicenter trials to considering confirmatory evidence such as natural history studies, mechanistic data, and data from other products in the same class. The episode emphasizes the importance of strategic planning and early consideration of data presentation in regulatory interactions.

The future episodes will focus on specific areas of the law, such as drug development, clinical trials, FDA compliance, and more, providing listeners with a detailed look at the complexities of pharmaceutical regulations and practical strategies for navigating them.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> In this episode host Phil Katz, discusses regulatory and legal trends in the pharma and biotech industries with Komal Karnik Nigam. They delve into the FDA's evolving approach to data packages required for drug approval, highlighting the increased flexibility in accepting alternative forms of evidence. Komal explains how FDA's guidance has shifted from demanding large, multicenter trials to considering confirmatory evidence such as natural history studies, mechanistic data, and data from other products in the same class. The episode emphasizes the importance of strategic planning and early consideration of data presentation in regulatory interactions.

The future episodes will focus on specific areas of the law, such as drug development, clinical trials, FDA compliance, and more, providing listeners with a detailed look at the complexities of pharmaceutical regulations and practical strategies for navigating them.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> In this episode of ”Pharma - The last word,” host Phil Katz, discusses regulatory and legal trends in the pharma and biotech industries with Komal Karnik Nigam. They delve into the FDA’s evolving approach to data packages required for drug approval, highlighting the increased flexibility in accepting alternative forms of evidence. Komal explains how FDA’s guidance has shifted from demanding large, multicenter trials to considering confirmatory evidence such as natural history studies, mechanistic data, and data from other products in the same class. The episode emphasizes the importance of strategic planning and early consideration of data presentation in regulatory interactions. Hogan Lovells false No 794 5 2 full Pharma – The Last Word - The inaugural episode Pharma – The Last Word - The inaugural episode https://talkingthecure.podbean.com/e/pharma-the-last-word-the-inaugural-episode/ https://talkingthecure.podbean.com/e/pharma-the-last-word-the-inaugural-episode/#comments Mon, 29 Apr 2024 21:33:37 +0200 talkingthecurebyhoganlovells.podbean.com/382d239b-e6ee-3cc6-b133-277af8a65525 Welcome to the inaugural episode of "Pharma – The Last Word", a podcast hosted by Partner Phil Katz from Hogan Lovells. This series aims to dive into the intricate world of pharmaceuticals and biotech regulatory and legal landscapes, exploring new innovations, trends, and their practical impacts. Join Phil and his first guest, Lynn Mehler, co-head of the Life Sciences and Health Care industry sector, and Lead of the Pharmaceuticals and Biotech Regulatory Practice, as they discuss the unique insights and deep expertise their team brings to the table, the largest of its kind outside the FDA. They will share the inner workings of their practice, how they stay ahead of industry trends, and their passion for the field.

Each episode will focus on specific areas of the law, such as drug development, clinical trials, FDA compliance, and more, providing listeners with a detailed look at the complexities of pharmaceutical regulations and practical strategies for navigating them.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

 

]]> Welcome to the inaugural episode of "Pharma – The Last Word", a podcast hosted by Partner Phil Katz from Hogan Lovells. This series aims to dive into the intricate world of pharmaceuticals and biotech regulatory and legal landscapes, exploring new innovations, trends, and their practical impacts. Join Phil and his first guest, Lynn Mehler, co-head of the Life Sciences and Health Care industry sector, and Lead of the Pharmaceuticals and Biotech Regulatory Practice, as they discuss the unique insights and deep expertise their team brings to the table, the largest of its kind outside the FDA. They will share the inner workings of their practice, how they stay ahead of industry trends, and their passion for the field.

Each episode will focus on specific areas of the law, such as drug development, clinical trials, FDA compliance, and more, providing listeners with a detailed look at the complexities of pharmaceutical regulations and practical strategies for navigating them.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

 

]]> A podcast hosted by Partner Phil Katz from Hogan Lovells. This series aims to dive into the intricate world of pharmaceuticals and biotech regulatory and legal landscapes, exploring new innovations, trends, and their practical impacts. Join Phil and his first guest, Lynn Mehler, co-head of the Life Sciences and Health Care industry sector, and Lead of the Pharmaceuticals and Biotech Regulatory Practice, as they discuss the unique insights and deep expertise their team brings to the table, the largest of its kind outside the FDA. They will share the inner workings of their practice, how they stay ahead of industry trends, and their passion for the field. Hogan Lovells false No 457 5 1 full Securing the Crown Jewels: Navigating IP and cybersecurity in the life science industry Securing the Crown Jewels: Navigating IP and cybersecurity in the life science industry https://talkingthecure.podbean.com/e/securing-the-crown-jewels-navigating-ip-and-cybersecurity-in-the-life-science-industry/ https://talkingthecure.podbean.com/e/securing-the-crown-jewels-navigating-ip-and-cybersecurity-in-the-life-science-industry/#comments Thu, 11 Apr 2024 09:09:00 +0200 ac968888-e079-40f4-a8ba-0a002c34cca7 In this episode of Talking the Cure Hogan Lovells Life Sciences and Health Care Podcast Ruud van der Velden and Chantal Van Dam highlight the importance of protecting intellectual property and trade secrets in the life sciences and health care industry. They discuss the legal framework for trade secrets in the EU, the increasing focus of cybercriminals on valuable company data beyond personal information, and provide key recommendations for companies to safeguard their most critical assets against theft and unauthorized disclosure.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> In this episode of Talking the Cure Hogan Lovells Life Sciences and Health Care Podcast Ruud van der Velden and Chantal Van Dam highlight the importance of protecting intellectual property and trade secrets in the life sciences and health care industry. They discuss the legal framework for trade secrets in the EU, the increasing focus of cybercriminals on valuable company data beyond personal information, and provide key recommendations for companies to safeguard their most critical assets against theft and unauthorized disclosure.

You can find additional thought leadership and information regarding digital health on Engage.

If you are interested in more information about Life Sciences and Health Care, follow us via ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠ and ⁠⁠⁠⁠Twitter⁠⁠⁠⁠.

]]> Hogan Lovells Cadwalader false No 1947 4 5 full Discussing UK medical device regulations Discussing UK medical device regulations https://talkingthecure.podbean.com/e/discussing-uk-medical-device-regulations/ https://talkingthecure.podbean.com/e/discussing-uk-medical-device-regulations/#comments Thu, 21 Mar 2024 14:15:00 +0100 baa0bf7d-3423-4199-b664-3fcf4f9ab39e Hogan Lovells Cadwalader false No 1027 4 4 full Talking the Cure - Exploring the industry with Richard Backhaus and Lars Cornels (Drägerwerk AG & Co. KGaA) - Part 2 Talking the Cure - Exploring the industry with Richard Backhaus and Lars Cornels (Drägerwerk AG & Co. KGaA) - Part 2 https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-richard-backhaus-and-lars-cornels-dragerwerk-ag-co-kgaa-part-2/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-richard-backhaus-and-lars-cornels-dragerwerk-ag-co-kgaa-part-2/#comments Thu, 29 Feb 2024 08:00:00 +0100 0f7e0439-54c6-4b1a-89eb-a15b24c1d4fc In the second part of the episode, ⁠⁠Arne Thiermann⁠⁠ is leading the conversation with ⁠⁠Richard Backhaus⁠⁠, and ⁠⁠Lars Cornels⁠⁠ discussing the integration and implications of digital health, artificial intelligence, and legal considerations in the medical device industry. They explore how traditional companies like ⁠⁠Drägerwerk AG & Co. KGaA⁠⁠ adapt to digital innovation, the role of AI and software in life sciences, and the challenges and opportunities presented by regulatory environments. They delve into specific legal frameworks, such as the European Union's data strategy and the AI Act, discussing their impact on innovation and data access. The conversation also touches on the practical use of AI in legal work, the future of the profession, and the broader implications of AI on society and human behavior.

You can find additional thought leadership and information regarding digital health on ⁠⁠⁠HL Engage⁠⁠⁠.

If you are interested in more information all around Life Sciences and Health Care, follow us on ⁠⁠⁠LinkedIn⁠⁠⁠ and ⁠⁠⁠Twitter⁠⁠⁠.

]]> In the second part of the episode, ⁠⁠Arne Thiermann⁠⁠ is leading the conversation with ⁠⁠Richard Backhaus⁠⁠, and ⁠⁠Lars Cornels⁠⁠ discussing the integration and implications of digital health, artificial intelligence, and legal considerations in the medical device industry. They explore how traditional companies like ⁠⁠Drägerwerk AG & Co. KGaA⁠⁠ adapt to digital innovation, the role of AI and software in life sciences, and the challenges and opportunities presented by regulatory environments. They delve into specific legal frameworks, such as the European Union's data strategy and the AI Act, discussing their impact on innovation and data access. The conversation also touches on the practical use of AI in legal work, the future of the profession, and the broader implications of AI on society and human behavior.


You can find additional thought leadership and information regarding digital health on ⁠⁠⁠HL Engage⁠⁠⁠.

If you are interested in more information all around Life Sciences and Health Care, follow us on ⁠⁠⁠LinkedIn⁠⁠⁠ and ⁠⁠⁠Twitter⁠⁠⁠.

]]> Hogan Lovells Cadwalader false No 1639 4 3 full Talking the Cure - Exploring the industry with Richard Backhaus and Lars Cornels (Drägerwerk AG & Co. KGaA) - Part 1 Talking the Cure - Exploring the industry with Richard Backhaus and Lars Cornels (Drägerwerk AG & Co. KGaA) - Part 1 https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-richard-backhaus-and-lars-cornels-dragerwerk-ag-co-kgaa-part-1/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-richard-backhaus-and-lars-cornels-dragerwerk-ag-co-kgaa-part-1/#comments Mon, 12 Feb 2024 08:00:00 +0100 0d085850-9884-4746-8434-3f09daeb61f4 In this first part of the episode, Arne Thiermann is leading the conversation with Richard Backhaus, and Lars Cornels discussing the integration and implications of digital health, artificial intelligence, and legal considerations in the medical device industry. They explore how traditional companies like Drägerwerk AG & Co. KGaA adapt to digital innovation, the role of AI and software in life sciences, and the challenges and opportunities presented by regulatory environments. They delve into specific legal frameworks, such as the European Union's data strategy and the AI Act, discussing their impact on innovation and data access. The conversation also touches on the practical use of AI in legal work, the future of the profession, and the broader implications of AI on society and human behavior.

You can find additional thought leadership and information regarding digital health on ⁠HL Engage⁠.

If you are interested in more information all around Life Sciences and Health Care, follow us on ⁠LinkedIn⁠ and ⁠Twitter⁠.

]]> In this first part of the episode, Arne Thiermann is leading the conversation with Richard Backhaus, and Lars Cornels discussing the integration and implications of digital health, artificial intelligence, and legal considerations in the medical device industry. They explore how traditional companies like Drägerwerk AG & Co. KGaA adapt to digital innovation, the role of AI and software in life sciences, and the challenges and opportunities presented by regulatory environments. They delve into specific legal frameworks, such as the European Union's data strategy and the AI Act, discussing their impact on innovation and data access. The conversation also touches on the practical use of AI in legal work, the future of the profession, and the broader implications of AI on society and human behavior.


You can find additional thought leadership and information regarding digital health on ⁠HL Engage⁠.

If you are interested in more information all around Life Sciences and Health Care, follow us on ⁠LinkedIn⁠ and ⁠Twitter⁠.

]]> Hogan Lovells Cadwalader false No 1764 4 2 full Talking the Cure - Exploring the industry with Robert F. Church Talking the Cure - Exploring the industry with Robert F. Church https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-robert-f-church/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-robert-f-church/#comments Wed, 24 Jan 2024 11:33:00 +0100 899202a5-2a4d-484b-821b-aa098468018e In this episode, Robert F. Church⁠ takes the time to look back on his career with us. We talk about what ultimately led him to become a lawyer, how he ended up at Hogan Lovells, and how he became the institution in clinical trials. Of course, we also talk about what it means to manage such a heavy workload, how he takes time to switch off, and what he would like to pass on to aspiring colleagues who would like to pursue a career in this field.

You can find additional thought leadership and information regarding digital health on HL Engage.

If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.

]]> In this episode, Robert F. Church⁠ takes the time to look back on his career with us. We talk about what ultimately led him to become a lawyer, how he ended up at Hogan Lovells, and how he became the institution in clinical trials. Of course, we also talk about what it means to manage such a heavy workload, how he takes time to switch off, and what he would like to pass on to aspiring colleagues who would like to pursue a career in this field.

You can find additional thought leadership and information regarding digital health on HL Engage.

If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.

]]> Hogan Lovells Cadwalader false No 2190 5 1 full Talking the Cure - Exploring the industry with Alice Valder Curran Talking the Cure - Exploring the industry with Alice Valder Curran https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-alice-valder-curran/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-alice-valder-curran/#comments Thu, 16 Nov 2023 13:13:00 +0100 talkingthecurebyhoganlovells.podbean.com/8ddf00cd-fc70-3e45-b76a-61fc55b65939 Hogan Lovells false No 2348 4 5 full Talking the Cure - Exploring the industry with Randy Prebula Talking the Cure - Exploring the industry with Randy Prebula https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-randy-prebula/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-randy-prebula/#comments Tue, 24 Oct 2023 00:30:00 +0200 talkingthecurebyhoganlovells.podbean.com/d664c775-9473-3b60-b510-e5698daa70af Hogan Lovells false No 2788 4 4 full Talking the Cure - Discussing the implications of the Inflation Reduction Act (IRA) Talking the Cure - Discussing the implications of the Inflation Reduction Act (IRA) https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-implications-of-the-inflation-reduction-act-ira/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-implications-of-the-inflation-reduction-act-ira/#comments Thu, 28 Sep 2023 11:19:00 +0200 talkingthecurebyhoganlovells.podbean.com/c1330f41-13b2-3261-b1cd-e824f60b1539 Hogan Lovells false No 1888 4 3 full Talking the Cure - Discussing latest developments​ іn clinical trials diversity, driven​ by FDORA Talking the Cure - Discussing latest developments​ іn clinical trials diversity, driven​ by FDORA https://talkingthecure.podbean.com/e/talking-the-cure-discussing-latest-developments%e2%80%8b-%d1%96n-clinical-trials-diversity-driven%e2%80%8b-by-fdora/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-latest-developments%e2%80%8b-%d1%96n-clinical-trials-diversity-driven%e2%80%8b-by-fdora/#comments Wed, 06 Sep 2023 11:52:00 +0200 talkingthecurebyhoganlovells.podbean.com/6889f14e-014d-3b8f-ac4e-4f7168e3f2f3 Hogan Lovells false No 1198 4 2 full Talking the Cure - Discussing Artificial Intelligence in Medical Devices Talking the Cure - Discussing Artificial Intelligence in Medical Devices https://talkingthecure.podbean.com/e/talking-the-cure-discussing-artificial-intelligence-in-medical-devices/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-artificial-intelligence-in-medical-devices/#comments Thu, 26 Jan 2023 06:00:00 +0100 talkingthecurebyhoganlovells.podbean.com/0f5af3c1-4ad1-3b0e-8195-0db6b06156be Hogan Lovells false No 2085 4 1 full Talking the Cure - Discussing MedTech Color with Kwame Ulmer Talking the Cure - Discussing MedTech Color with Kwame Ulmer https://talkingthecure.podbean.com/e/talking-the-cure-discussing-medtech-color-with-kwame-ulmer/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-medtech-color-with-kwame-ulmer/#comments Mon, 14 Nov 2022 00:00:00 +0100 talkingthecurebyhoganlovells.podbean.com/7d22d83c-f7e2-3595-a7c4-98b3467e8d61 Hogan Lovells false No 1278 3 7 full Talking the Cure - Exploring the industry with Ina Brock Talking the Cure - Exploring the industry with Ina Brock https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-ina-brock/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-ina-brock/#comments Wed, 28 Sep 2022 00:00:00 +0200 talkingthecurebyhoganlovells.podbean.com/1d01dd1e-ab5c-357b-86e4-d078b173a721 Hogan Lovells false No 2924 3 6 full Talking the Cure - Discussing diversity in clinical trials Talking the Cure - Discussing diversity in clinical trials https://talkingthecure.podbean.com/e/talking-the-cure-discussing-diversity-in-clinical-trials/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-diversity-in-clinical-trials/#comments Thu, 28 Jul 2022 09:13:00 +0200 talkingthecurebyhoganlovells.podbean.com/e0c032f0-1c8c-3da6-baa4-dcbec0f61586 Hogan Lovells false No 2162 3 6 full Talking the Cure - Discussing the repurpose of existing UK offices/retail to laboratory space? Talking the Cure - Discussing the repurpose of existing UK offices/retail to laboratory space? https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-repurpose-of-existing-uk-officesretail-to-laboratory-space/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-repurpose-of-existing-uk-officesretail-to-laboratory-space/#comments Mon, 20 Jun 2022 10:33:00 +0200 talkingthecurebyhoganlovells.podbean.com/9b6b52a3-575a-3060-8627-85a7d7a7528d Hogan Lovells false No 1929 3 5 full Talking the Cure - Discussing what’s on the horizons for orthopedic devices Talking the Cure - Discussing what’s on the horizons for orthopedic devices https://talkingthecure.podbean.com/e/talking-the-cure-discussing-what-s-on-the-horizons-for-orthopedic-devices/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-what-s-on-the-horizons-for-orthopedic-devices/#comments Thu, 19 May 2022 00:01:00 +0200 talkingthecurebyhoganlovells.podbean.com/b261c5c5-2469-350a-80f4-83fe542fe825 Hogan Lovells false No 1886 3 4 full Talking the Cure - Exploring the industry with Andreas von Falck Talking the Cure - Exploring the industry with Andreas von Falck https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-andreas-von-falck/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-andreas-von-falck/#comments Thu, 14 Apr 2022 00:00:00 +0200 talkingthecurebyhoganlovells.podbean.com/fed2e2d8-d6b2-3f2f-9fd7-7c60054b270e Hogan Lovells false No 2074 3 3 full Talking the Cure: Discussing Digital Health Applications in Germany Talking the Cure: Discussing Digital Health Applications in Germany https://talkingthecure.podbean.com/e/talking-the-cure-discussing-digital-health-applications-in-germany/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-digital-health-applications-in-germany/#comments Wed, 23 Mar 2022 23:01:00 +0100 talkingthecurebyhoganlovells.podbean.com/7ac35e93-1de6-3cd6-a689-b8ea3cb433ba Hogan Lovells false No 2084 3 2 full Talking the Cure - Exploring the industry with Jonathan S. Kahan Talking the Cure - Exploring the industry with Jonathan S. Kahan https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-jonathan-s-kahan/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-jonathan-s-kahan/#comments Wed, 02 Mar 2022 11:30:00 +0100 talkingthecurebyhoganlovells.podbean.com/1ecb1fba-ef44-384d-9d28-e76dd8281405 Hogan Lovells false No 2677 3 1 full Talking the Cure: Discussing Early Access Programs (EAPs) in the US and Germany Talking the Cure: Discussing Early Access Programs (EAPs) in the US and Germany https://talkingthecure.podbean.com/e/talking-the-cure-discussing-early-access-programs-eaps-in-the-us-and-germany/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-early-access-programs-eaps-in-the-us-and-germany/#comments Thu, 16 Dec 2021 11:34:00 +0100 talkingthecurebyhoganlovells.podbean.com/696a7693-f3d5-3389-875b-e0bf22707723 Hogan Lovells false No 1998 2 9 full Talking The Cure: Exploring the industry with Christian Di Mauro Talking The Cure: Exploring the industry with Christian Di Mauro https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-christian-di-mauro/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-christian-di-mauro/#comments Wed, 01 Dec 2021 11:02:00 +0100 talkingthecurebyhoganlovells.podbean.com/7bd2677e-d088-36e3-beae-03dec94e5db8 Hogan Lovells false No 1810 2 9 full Talking The Cure: Discussing return to work policies, testing at work sites, and vaccinations Talking The Cure: Discussing return to work policies, testing at work sites, and vaccinations https://talkingthecure.podbean.com/e/talking-the-cure-discussing-return-to-work-policies-testing-at-work-sites-and-vaccinations/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-return-to-work-policies-testing-at-work-sites-and-vaccinations/#comments Tue, 06 Jul 2021 12:32:00 +0200 talkingthecurebyhoganlovells.podbean.com/9510df1e-d929-3883-a98d-e44978a7e18e Hogan Lovells false No 1994 2 8 full Talking The Cure: Exploring the industry with Lowell Zeta Talking The Cure: Exploring the industry with Lowell Zeta https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-lowell-zeta/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-lowell-zeta/#comments Tue, 15 Jun 2021 14:06:00 +0200 talkingthecurebyhoganlovells.podbean.com/82bd21c1-c180-3bd9-b23e-e7b1929e4de3 Hogan Lovells false No 1859 2 7 full Talking The Cure: Discussing the impact of Covid-19 on cell, tissue, and gene therapy products Talking The Cure: Discussing the impact of Covid-19 on cell, tissue, and gene therapy products https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-impact-of-covid-19-on-cell-tissue-and-gene-therapy-products/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-impact-of-covid-19-on-cell-tissue-and-gene-therapy-products/#comments Thu, 06 May 2021 14:30:00 +0200 talkingthecurebyhoganlovells.podbean.com/6389c581-3123-3d87-93c6-152114aa491e Hogan Lovells false No 3210 2 6 full Talking The Cure: Discussing advertising and promotion of COVID-19 test kits Talking The Cure: Discussing advertising and promotion of COVID-19 test kits https://talkingthecure.podbean.com/e/talking-the-cure-discussing-advertising-and-promotion-of-covid-19-test-kits/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-advertising-and-promotion-of-covid-19-test-kits/#comments Thu, 15 Apr 2021 14:22:00 +0200 talkingthecurebyhoganlovells.podbean.com/fe02874c-7370-3b32-86fd-df8973411833 Hogan Lovells false No 2390 2 5 full Talking The Cure: Discussing hand sanitizers and their way to the market Talking The Cure: Discussing hand sanitizers and their way to the market https://talkingthecure.podbean.com/e/talking-the-cure-discussing-hand-sanitizers-and-their-way-to-the-market/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-hand-sanitizers-and-their-way-to-the-market/#comments Mon, 08 Mar 2021 15:47:00 +0100 talkingthecurebyhoganlovells.podbean.com/7990e34a-1ea0-3118-8913-789c3bfc9f5a Hogan Lovells false No 1878 2 3 full Talking The Cure: Discussing the current ”surge” of Digital Health Innovations in Europe Talking The Cure: Discussing the current ”surge” of Digital Health Innovations in Europe https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-current-surge-of-digital-health-innovations-in-europe/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-current-surge-of-digital-health-innovations-in-europe/#comments Tue, 16 Feb 2021 11:00:00 +0100 talkingthecurebyhoganlovells.podbean.com/69c8f673-0096-3a03-a146-fa7053a55e2b Hogan Lovells false No 3167 2 2 full Talking The Cure: Exploring the industry with Jodi Scott Talking The Cure: Exploring the industry with Jodi Scott https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-jodi-scott/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-jodi-scott/#comments Thu, 21 Jan 2021 17:14:00 +0100 talkingthecurebyhoganlovells.podbean.com/64a99a49-2ef0-381d-b350-04dcebec9649 Hogan Lovells false No 1791 2 1 full Talking The Cure: Exploring the industry with the leads of our associate committee Talking The Cure: Exploring the industry with the leads of our associate committee https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-the-leads-of-our-associate-committee/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-the-leads-of-our-associate-committee/#comments Mon, 21 Dec 2020 17:46:00 +0100 talkingthecurebyhoganlovells.podbean.com/27bae0c8-d874-3400-806f-8b16a78f9e78 Hogan Lovells false No 2435 1 20 full Talking The Cure: Discussing artificial intelligence in drug discovery and the possible legal issues that result from this usage. Talking The Cure: Discussing artificial intelligence in drug discovery and the possible legal issues that result from this usage. https://talkingthecure.podbean.com/e/talking-the-cure-discussing-artificial-intelligence-in-drug-discovery-and-the-possible-legal-issues-that-result-from-this-usage/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-artificial-intelligence-in-drug-discovery-and-the-possible-legal-issues-that-result-from-this-usage/#comments Thu, 03 Dec 2020 09:50:00 +0100 talkingthecurebyhoganlovells.podbean.com/2951211e-bcb0-308f-81ce-564c38b7c996 Hogan Lovells false No 2296 1 19 full Talking The Cure: Discussing in vitro diagnostics (IVD) in times of a pandemic Talking The Cure: Discussing in vitro diagnostics (IVD) in times of a pandemic https://talkingthecure.podbean.com/e/talking-the-cure-discussing-in-vitro-diagnostics-ivd-in-times-of-a-pandemic/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-in-vitro-diagnostics-ivd-in-times-of-a-pandemic/#comments Fri, 13 Nov 2020 10:56:00 +0100 talkingthecurebyhoganlovells.podbean.com/92f51c58-02c9-3b23-bdb0-41957da726cf Hogan Lovells false No 2083 1 18 full Talking The Cure: Exploring the industry with Jonathan Wasserman Talking The Cure: Exploring the industry with Jonathan Wasserman https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-jonathan-wasserman/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-jonathan-wasserman/#comments Wed, 21 Oct 2020 17:03:00 +0200 talkingthecurebyhoganlovells.podbean.com/e2c63078-5855-3036-bb85-d1263ea2e25d Hogan Lovells false No 2246 1 17 full Talking The Cure: Discussing the “Buy America” Executive Order Talking The Cure: Discussing the “Buy America” Executive Order https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-buy-america-executive-order/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-buy-america-executive-order/#comments Mon, 12 Oct 2020 17:33:00 +0200 talkingthecurebyhoganlovells.podbean.com/3d475539-f72e-3828-b1db-8b531600d8e8 Hogan Lovells false No 3267 1 16 full Talking The Cure: Discussing opportunities and risks for international digital health companies engaging in Germany Talking The Cure: Discussing opportunities and risks for international digital health companies engaging in Germany https://talkingthecure.podbean.com/e/talking-the-cure-discussing-opportunities-and-risks-for-international-digital-health-companies-engaging-in-germany/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-opportunities-and-risks-for-international-digital-health-companies-engaging-in-germany/#comments Mon, 12 Oct 2020 16:42:00 +0200 talkingthecurebyhoganlovells.podbean.com/4b465007-c255-33e5-9177-f460330727df Hogan Lovells false No 2158 1 15 full Talking The Cure: Discussing innovation in drug development, the competitive aspects and affordability of medicines in Europe Talking The Cure: Discussing innovation in drug development, the competitive aspects and affordability of medicines in Europe https://talkingthecure.podbean.com/e/talking-the-cure-discussing-innovation-in-drug-development-the-competitive-aspects-and-affordability-of-medicines-in-europe/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-innovation-in-drug-development-the-competitive-aspects-and-affordability-of-medicines-in-europe/#comments Mon, 12 Oct 2020 16:38:00 +0200 talkingthecurebyhoganlovells.podbean.com/e94dbfbd-f938-3ad7-aecf-650581ed74fa Hogan Lovells false No 891 1 14 full Talking The Cure: Discussing recent industry developments with the Hogan Lovells Sciences Unit Talking The Cure: Discussing recent industry developments with the Hogan Lovells Sciences Unit https://talkingthecure.podbean.com/e/talking-the-cure-discussing-recent-industry-developments-with-the-hogan-lovells-sciences-unit/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-recent-industry-developments-with-the-hogan-lovells-sciences-unit/#comments Mon, 12 Oct 2020 16:33:00 +0200 talkingthecurebyhoganlovells.podbean.com/7b16fce0-6700-3a09-9f71-786917de4459 Hogan Lovells false No 2672 1 13 full Talking The Cure: Discussing the rise of telehealth in the life sciences and health care industry Talking The Cure: Discussing the rise of telehealth in the life sciences and health care industry https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-rise-of-telehealth-in-the-life-sciences-and-health-care-industry/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-rise-of-telehealth-in-the-life-sciences-and-health-care-industry/#comments Mon, 12 Oct 2020 16:10:00 +0200 talkingthecurebyhoganlovells.podbean.com/93aad7be-ac06-3186-a5dc-7dca5ff88950 Hogan Lovells false No 1790 1 12 full Talking The Cure: Exploring the industry with Philip Katz - Part 2 Talking The Cure: Exploring the industry with Philip Katz - Part 2 https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-philip-katz-part-2/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-philip-katz-part-2/#comments Mon, 12 Oct 2020 15:38:00 +0200 talkingthecurebyhoganlovells.podbean.com/6b28709c-f74b-3b8d-9815-568eebae917a Hogan Lovells false No 1357 1 11 full Talking The Cure: Exploring the industry with Philip Katz - Part 1 Talking The Cure: Exploring the industry with Philip Katz - Part 1 https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-philip-katz-part-1/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-philip-katz-part-1/#comments Mon, 12 Oct 2020 15:21:00 +0200 talkingthecurebyhoganlovells.podbean.com/8c9ce131-2455-31e9-bb93-e5d8eda6b102 Hogan Lovells false No 1410 1 10 full Talking the Cure: Discussing venture capital in the life sciences and health care sector in Germany Talking the Cure: Discussing venture capital in the life sciences and health care sector in Germany https://talkingthecure.podbean.com/e/talking-the-cure-discussing-venture-capital-in-the-life-sciences-and-health-care-sector-in-germany/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-venture-capital-in-the-life-sciences-and-health-care-sector-in-germany/#comments Mon, 12 Oct 2020 15:04:00 +0200 talkingthecurebyhoganlovells.podbean.com/255ba0f0-6af9-39ec-a295-4315ba22654f Hogan Lovells false No 1529 1 9 full Talking The Cure: Discussing European developments on Covid-19 Talking The Cure: Discussing European developments on Covid-19 https://talkingthecure.podbean.com/e/talking-the-cure-discussing-european-developments-on-covid-19/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-european-developments-on-covid-19/#comments Mon, 12 Oct 2020 14:25:00 +0200 talkingthecurebyhoganlovells.podbean.com/ce4851a1-d183-35e5-809c-d1b091609c9b Hogan Lovells false No 1555 1 8 full Talking The Cure: Discussing reimbursement issues in France and the MDR Talking The Cure: Discussing reimbursement issues in France and the MDR https://talkingthecure.podbean.com/e/talking-the-cure-discussing-reimbursement-issues-in-france-and-the-mdr/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-reimbursement-issues-in-france-and-the-mdr/#comments Mon, 12 Oct 2020 14:18:00 +0200 talkingthecurebyhoganlovells.podbean.com/06a51b77-f1fe-31c7-94bc-44bca9883aa1 Hogan Lovells false No 676 1 7 full Talking the Cure: Discussing COVID-19’s impact on FDA’s inspection program and next steps after the pandemic Talking the Cure: Discussing COVID-19’s impact on FDA’s inspection program and next steps after the pandemic https://talkingthecure.podbean.com/e/talking-the-cure-discussing-covid-19-s-impact-on-fda-s-inspection-program-and-next-steps-after-the-pandemic/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-covid-19-s-impact-on-fda-s-inspection-program-and-next-steps-after-the-pandemic/#comments Mon, 12 Oct 2020 14:14:00 +0200 talkingthecurebyhoganlovells.podbean.com/f33f59d2-bd63-34a3-8f33-94fa2f181d8f Hogan Lovells false No 1622 1 6 full Talking The Cure: Discussing how the coronavirus pandemic is affecting the pharmaceutical industry and FDA Talking The Cure: Discussing how the coronavirus pandemic is affecting the pharmaceutical industry and FDA https://talkingthecure.podbean.com/e/talking-the-cure-discussing-how-the-coronavirus-pandemic-is-affecting-the-pharmaceutical-industry-and-fda/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-how-the-coronavirus-pandemic-is-affecting-the-pharmaceutical-industry-and-fda/#comments Mon, 12 Oct 2020 13:35:00 +0200 talkingthecurebyhoganlovells.podbean.com/4c033a21-93d9-3c69-99ba-f7841784941e Hogan Lovells false No 1104 1 5 full Talking The Cure: Discussing FDA authorities for handling a global pandemic for medical devices Talking The Cure: Discussing FDA authorities for handling a global pandemic for medical devices https://talkingthecure.podbean.com/e/talking-the-cure-discussing-fda-authorities-for-handling-a-global-pandemic-for-medical-devices/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-fda-authorities-for-handling-a-global-pandemic-for-medical-devices/#comments Mon, 12 Oct 2020 12:53:00 +0200 talkingthecurebyhoganlovells.podbean.com/b6684dd3-6921-3832-b8b0-20a07c2cc316 Hogan Lovells false No 1648 1 4 full Talking the Cure: Discussing the supply chain and its potential downfalls Talking the Cure: Discussing the supply chain and its potential downfalls https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-supply-chain-and-its-potential-downfalls/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-supply-chain-and-its-potential-downfalls/#comments Mon, 12 Oct 2020 12:42:00 +0200 talkingthecurebyhoganlovells.podbean.com/a114695a-7294-39e6-b697-ac46b53cc4ed Hogan Lovells false No 1633 1 3 full Talking The Cure: Exploring the industry with Jörg Schickert Talking The Cure: Exploring the industry with Jörg Schickert https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-jorg-schickert/ https://talkingthecure.podbean.com/e/talking-the-cure-exploring-the-industry-with-jorg-schickert/#comments Mon, 12 Oct 2020 12:39:00 +0200 talkingthecurebyhoganlovells.podbean.com/edbd066b-5f4d-36b4-8492-b7e20edf3d31 Hogan Lovells false No 1228 1 2 full Talking The Cure: Discussing the use of digital tools in clinical trials Talking The Cure: Discussing the use of digital tools in clinical trials https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-use-of-digital-tools-in-clinical-trials/ https://talkingthecure.podbean.com/e/talking-the-cure-discussing-the-use-of-digital-tools-in-clinical-trials/#comments Mon, 12 Oct 2020 12:22:00 +0200 talkingthecurebyhoganlovells.podbean.com/e933f3b6-8dea-3d15-8e54-a572b67ffbc8 Hogan Lovells false No 961 1 1 full